These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 27707716)

  • 1. 80% of China's clinical trial data are fraudulent, investigation finds.
    Woodhead M
    BMJ; 2016 Oct; 355():i5396. PubMed ID: 27707716
    [No Abstract]   [Full Text] [Related]  

  • 2. China cracks down on fake data in drug trials.
    Cyranoski D
    Nature; 2017 May; 545(7654):275. PubMed ID: 28516939
    [No Abstract]   [Full Text] [Related]  

  • 3. Pharmaceutical companies liable for fraudulent research by subcontractors.
    Nolan KJ
    Drug Discov Today; 2004 Feb; 9(4):153-4. PubMed ID: 14960392
    [No Abstract]   [Full Text] [Related]  

  • 4. EU directive on clinical trials penalizes small sponsors.
    Meldolesi A
    Nat Biotechnol; 2003 Aug; 21(8):838. PubMed ID: 12894186
    [No Abstract]   [Full Text] [Related]  

  • 5. Indian Supreme Court halts approval of new clinical trials until regulatory framework is set up.
    Bagcchi S
    BMJ; 2013 Oct; 347():f5996. PubMed ID: 24097130
    [No Abstract]   [Full Text] [Related]  

  • 6. Fraud and misconduct in clinical research: is it prejudicial to patient safety?
    Wells F
    Adverse Drug React Toxicol Rev; 1992; 11(4):241-55. PubMed ID: 1489884
    [No Abstract]   [Full Text] [Related]  

  • 7. Researchers break the rules in frustration at review boards.
    Giles J
    Nature; 2005 Nov; 438(7065):136-7. PubMed ID: 16280994
    [No Abstract]   [Full Text] [Related]  

  • 8. Trouble at the office.
    Allison M
    Nat Biotechnol; 2008 Sep; 26(9):967-9. PubMed ID: 18779797
    [No Abstract]   [Full Text] [Related]  

  • 9. Drug companies should release data from all trials of licensed drugs, say MPs.
    Hawkes N
    BMJ; 2013 Jan; 346():f321. PubMed ID: 23325880
    [No Abstract]   [Full Text] [Related]  

  • 10. Cautious welcome for FDA pharmacogenomics guidance.
    Katsnelson A;
    Nat Biotechnol; 2005 May; 23(5):510. PubMed ID: 15877053
    [No Abstract]   [Full Text] [Related]  

  • 11. Industry looks to buck bias in emerging 'adaptive' designs.
    Torres C
    Nat Med; 2010 Jun; 16(6):619. PubMed ID: 20526301
    [No Abstract]   [Full Text] [Related]  

  • 12. Pharmaceuticals and medical devices: FDA oversight. End-of-year issue brief.
    Chaps NA
    Issue Brief Health Policy Track Serv; 2010 Jan; ():1-31. PubMed ID: 20217914
    [No Abstract]   [Full Text] [Related]  

  • 13. Correspondence (letter to the editor): Search bias.
    Braschoss A
    Dtsch Arztebl Int; 2010 Sep; 107(38):671-2; author reply 673-4. PubMed ID: 20953260
    [No Abstract]   [Full Text] [Related]  

  • 14. The EMEA guideline on first-in-human clinical trials and its impact on pharmaceutical development.
    Milton MN; Horvath CJ
    Toxicol Pathol; 2009 Apr; 37(3):363-71. PubMed ID: 19246571
    [No Abstract]   [Full Text] [Related]  

  • 15. China's deadly drug problem.
    Cyranoski D
    Nature; 2007 Apr; 446(7136):598-9. PubMed ID: 17410150
    [No Abstract]   [Full Text] [Related]  

  • 16. China's perspective on similar biotherapeutic products.
    Liang C; Wang J
    Biologicals; 2011 Sep; 39(5):312-6. PubMed ID: 21924622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correspondence (letter to the editor): National foundation.
    Freund M
    Dtsch Arztebl Int; 2010 Sep; 107(38):671; author reply 673-4. PubMed ID: 20953259
    [No Abstract]   [Full Text] [Related]  

  • 18. Correspondence (letter to the editor): Notorious weaknesses.
    Maares J
    Dtsch Arztebl Int; 2010 Sep; 107(38):670; author reply 673-4. PubMed ID: 20953258
    [No Abstract]   [Full Text] [Related]  

  • 19. Reforming China's drug regulatory system.
    Xu L; Gao H; Kaitin KI; Shao L
    Nat Rev Drug Discov; 2018 Dec; 17(12):858-859. PubMed ID: 30262888
    [No Abstract]   [Full Text] [Related]  

  • 20. The unintended consequences of clinical trials regulations.
    McMahon AD; Conway DI; Macdonald TM; McInnes GT
    PLoS Med; 2009 Nov; 3(11):e1000131. PubMed ID: 19918557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.